Figure 2: PIK3CA and ESR1 mutation analysis of matched tissue and plasma samples. | Nature Communications

Figure 2: PIK3CA and ESR1 mutation analysis of matched tissue and plasma samples.

From: Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant

Figure 2

(a) PIK3CA and ESR1 mutation analysis of matched tumour tissue and plasma samples from 142 patients from part 1 of the clinical study. Mutations are coloured according to exon (PIK3CA) or amino acid (ESR1). Grey indicates mutations assessed were negative, and blank indicates data not available. (b) ESR1 tissue and matched plasma mutation status from 102 part 1 and part 2 patients. Patients whose tissue was collected after receiving AI therapy shown on the left (21), and those whose tissue was collected before AI on the right (81). Tissue collection at the time of primary or metastatic disease indicated with open or solid squares, respectively.

Back to article page